Merrion granted US drug permit

Dublin: Drugs development firm, Merrion Pharmaceuticals, has been granted a further patent in the US protecting its key Orazol product.

The company’s tablets are an oral form of zoledronic acid which is in development as a treatment for bone metastases associated with prostate, breast and other cancers. It is a patent specific to Merrion’s Orazol product and has an expiry date of 2027.